Effectiveness of SGLT2 inhibitors compared to sulphonylureas for long-term glycemic control in type 2 diabetes: A meta-analysis
Abstract
Sulphonylureas (SUs) are common glucose-lowering agents used for managing type 2 diabetes mellitus (T2DM). However, their long-term effectiveness is often limited due to declining β-cell function. Sodium-glucose co-transporter 2 (SGLT2) inhibitors act independently of insulin, potentially providing more sustained glycemic control. Nonetheless, comparative data regarding the long-term glycemic durability of these two drug classes are limited. We performed a meta-analysis of head-to-head randomized controlled trials (RCTs) comparing the efficacy of SGLT2 inhibitors versus SUs in patients with T2DM already receiving metformin therapy. Eligible studies reported HbA1c values at intermediate (24-28 weeks or 48-52 weeks) and final (96-104 weeks or 208 weeks) time points, with a minimum follow-up duration of 96 weeks. Pooled mean differences (MD) and their 95% confidence intervals (CIs) were calculated using random-effects models. Seven comparisons from five RCTs were included in our analysis. Compared with SUs, SGLT2 inhibitors were associated with significantly smaller increases in HbA1c over time. From 24-28 weeks to 96-104 weeks, the pooled MD was -0.28% (95% CI: -0.35 to -0.20; p < 0.001; I² = 0%). From 48-52 weeks to 96-104 weeks, the MD was -0.11% (95% CI: -0.19 to -0.04; p = 0.004; I² = 0%). In longer-term analyses, SGLT2 inhibitors demonstrated sustained benefits from 52 weeks to 208 weeks (MD: -0.22%; 95% CI: -0.34 to -0.10; p < 0.001) and from 104 weeks to 208 weeks (MD:…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.